Food and Drug Administration Commissioner Marty Makary has taken a personal interest in addressing hormone therapy treatment for menopause. His comments come as part of a broader discussion on the lack of funding and research in women’s health care. Makary highlighted the need to address the ‘male-dominated’ culture of medical research, which has historically overlooked women’s health needs.
During a recent appearance on The Conversation, Makary emphasized that the current state of research in women’s health is inadequate, particularly in areas such as hormone therapy for menopause. He pointed out that the medical research landscape has been predominantly shaped by male-focused studies, leading to a gap in understanding and addressing women’s unique health challenges. This lack of attention has resulted in limited treatment options and a lack of robust data on the long-term effects of certain therapies.
Makary’s advocacy for greater investment in women’s health research aligns with recent calls for more inclusive and gender-specific research in the medical field. Advocacy groups and medical professionals have joined in supporting these efforts, arguing that such research is essential for improving healthcare outcomes for women. The FDA’s stance on this issue could have significant implications for future medical research and regulatory policies in the United States.